By: Benzinga
August 16, 2013 at 10:51 AM EDT
UPDATE: Aegis Capital Upgrades Sinovac Biotech Following 2Q 2013 Financial Results
In a report published Friday, Aegis Capital analyst Brian Rockowitz upgraded Sinovac Biotech (NASDAQ: SVA ) from Hold to Buy, and named a $7.00 price target. In the report, Aegis Capital noted, “Yesterday, Sinovac reported 2Q 2013 financial results. Total revenue was reported at $17.5mm, beating our projection of $11.6mm. Diluted earnings
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here